Michael Wheatcroft
Chief Tech/Sci/R&D Officer presso TELIX PHARMACEUTICALS LIMITED
Profilo
Michael Wheatcroft is currently the Chief Scientist at Telix Pharmaceuticals Ltd.
He previously worked as a Principal at Medimmune UK Ltd.
and as a Research Manager at Avipep Pty Ltd.
He holds a doctorate degree from the University of Cambridge.
Posizioni attive di Michael Wheatcroft
| Società | Posizione | Inizio |
|---|---|---|
| TELIX PHARMACEUTICALS LIMITED | Chief Tech/Sci/R&D Officer | - |
Precedenti posizioni note di Michael Wheatcroft
| Società | Posizione | Fine |
|---|---|---|
Medimmune UK Ltd.
 Medimmune UK Ltd. Chemicals: Major DiversifiedProcess Industries Medimmune UK Ltd. manufactures chemical products. The company was founded on October 6, 1999 and is headquartered in Speke, the United Kingdom. | Corporate Officer/Principal | - |
Avipep Pty Ltd.
 Avipep Pty Ltd. Medical SpecialtiesHealth Technology Avipep Pty Ltd. commercializes protein biopharmaceuticals and in-vivo diagnostic products. It focuses on developing Avibodies as a platform for targeting cells in the body with a focus on antibody-drug conjugates (ADC) for the treatment of cancer. The company was founded on April 7, 2005 and is headquartered in Parkville, Australia. | Corporate Officer/Principal | - |
Formazione di Michael Wheatcroft
| University of Cambridge | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| TELIX PHARMACEUTICALS LIMITED | Health Technology |
| Aziende private | 2 |
|---|---|
Medimmune UK Ltd.
Medimmune UK Ltd. Chemicals: Major DiversifiedProcess Industries Medimmune UK Ltd. manufactures chemical products. The company was founded on October 6, 1999 and is headquartered in Speke, the United Kingdom. | Process Industries |
Avipep Pty Ltd.
Avipep Pty Ltd. Medical SpecialtiesHealth Technology Avipep Pty Ltd. commercializes protein biopharmaceuticals and in-vivo diagnostic products. It focuses on developing Avibodies as a platform for targeting cells in the body with a focus on antibody-drug conjugates (ADC) for the treatment of cancer. The company was founded on April 7, 2005 and is headquartered in Parkville, Australia. | Health Technology |
- Borsa valori
- Insiders
- Michael Wheatcroft
